Umoja Biopharma
umoja-biopharma.com
Actively hiring
Biologics & Biosimilars
Cell & Gene Therapy
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$210M
1 round on record
Latest round
$210M
Venture round · Jun 2021 · 5 yr ago
Team
164
US Form 5500 (plan participants) · Dec 2024
Hiring now
5
+3 posted in 30 days
Backers
1
MPM BioImpact
The money's age
Long since its last round
64 months since the last round · and hiring
Momentum
34/100
hiring for its size, a new city
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 31, 2024
Certified Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR T for Hematologic Malignancies · streetinsider.com
Aug 24, 2021
Board appointment Umoja Biopharma Appoints Greg Sargen to its Board of Directors · markets.businessinsider.com
Jun 9, 2021
Raised a round Venture round $210M · SEC Form D
2019
Founded
Tractionpublic signals, read monthly
Web presence
top 5%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jun 2021 | $210M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Umoja Biopharma, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Irena MelnikovaExecutive OfficerSEC Form D
Andrew ScharenbergExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
MPM BioImpact Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Cancer immunotherapy that turns cancer cells into biofactories minting their own destruction.
ALKemist Bio is a biotech startup developing next-generation T cell therapies that target ALK-positive cancers. By reprogramming the immune…
ProtaGene is a world-leading CRO partner for the biopharmaceutical and gene and cell therapy industries.
Reprogramming is the next leap forward in cancer immunotherapy. Asgard Therapeutics is a Swedish private biotech company exploring direct…
At Strike Pharma we are shaping a new era of immunotherapy by using our ADAC technology.
Signadori Bio is a preclinical stage biopharmaceutical company developing a next generation in vivo monocyte immunotherapy to treat solid…
News
Umoja Biopharma Announces Unveiling of UB-VV500 in Upcoming Poster Presentation at the American Society of Gene & Cell Therapy Annual Meeting
Read more
Report
Report
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV111, a CD19 Directed in situ CAR T for Hematologic Malignancies
Read more
Report
Taking the stage at SXSW 2024
By: Andy Scharenberg, M.D., co-founder and Chief Executive Officer Where the arts and science meetI had the opportunity to speak on a panel at one of the largest conferences hosted in the U.S. each year: SXSW (South by Southwest). Founded in 1987, SXSW is
Read more
Report
AbbVie Collaborates With Umoja Biopharma To Develop Novel In-Situ CAR-T Cell Therapies
(RTTNews) - On Thursday, drug manufacturer AbbVie Inc. (ABBV) announced two exclusive options and license agreements with Umoja Biopharma, a clinical-stage biotechnology company to develop multiple in-situ CAR-T cell therapy for patients with cancer.
Read more
Report
Building internal manufacturing as a preclinical company
By: Ryan Crisman, Ph.D., co-founder and Chief Technical Officer IntroductionIn the fast-paced landscape of biotechnology, the demand for advanced tools and techniques is on a relentless rise. Lentiviral vectors (LVVs), which are a cornerstone in immunolog
Read more
Report
Umoja Biopharma to Unveil Preliminary Positive Non-Human Primate Data for the First Time at the 8th CAR-TCR Summit
Read more
Report
Ozette Technologies Announces New Collaboration with Umoja Biopharma to Accelerate Biomarker Discovery in Preclinical Studies
Read more
Report
Reflecting on Women's History Month - A look at progress in breast cancer treatments
By: Teisha Rowland, Ph.D., Principal Scientist Last fall, I felt a lump in my breast. After debating for a few days about what to do - Had it been there before, and I just hadn't noticed it? Should I be concerned about it? - I ended up calling my Obstetri
Read more
Report
Learning from history - Umoja's approach to overcoming CAR T therapy treatment challenges and limitations
Ten years ago, a little girl was in the battle of her life against a foe she couldn't possibly comprehend. Two years previously, she was diagnosed with acute lymphoblastic leukemia at the age of 5. No parent wants to receive the news that their child has
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Umoja Biopharma over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
64/100
Cloud & platforms
GCP
Sign in to see how your skills match this stack
Sign In
Salary insights
Compensation ranges based on this company's open jobs
Median
$267k
Typical range
$197k – $368k
Open positions
4
4
Jobs
Senior
50%
Architect
50%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 2 | $253k | $197k – $309k |
| Architect | 2 | $297k | $226k – $368k |
Highest paying role
Executive Director, Corporate Securities Counsel
$368k
Normalized to USD per year
People
Irena Melnikova
Executive Officer
Andrew Scharenberg
Executive Officer, Director
Philip Low
Director
Anna French
Director
Robert Glassman
Director
John Hamer
Director
Luke Evnin
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Growth
Hiring Momentum
48/100
Stable
Open positions
5
1 opened / 0 closed in 30 days
Median time-to-fill
60 days
faster than 22% of the market
ATS activity
Every ~4 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Legal
40% ▼
HR
20% ▼
Operations
20% ▲
Public Policy
20% ▲
Activity Timeline
Added Smartsheet to stack
Oct 2026
Added Microsoft Office to stack
Oct 2026
New location: Louisville
Sep 2026
Added Windows to stack
Sep 2026
Added HIPAA to stack
Sep 2026
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
2
Countries
1
Busiest office
Seattle
Loading the map
Headquarters
Builds here
Office with open vacancies
Tap a pin for the office
Seattle
United States
HQ
Seattle
3 open roles 4 posted in 90 days 67% remote $264k Avg Salary
hires for Legal, Public Policy
Louisville
United States
Regional office
Louisville
2 open roles 1 posted in 90 days 50% remote $309k Avg Salary
hires for Operations, Public Policy
Financials
Total raised
$210M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2021 | $210M | Details |